摘要
目的探讨依达拉奉右莰醇联合丁苯酞治疗短暂性脑缺血发作(TIA)的临床疗效。方法选取医院2022年3月至2023年3月收治的TIA患者120例,按治疗方案的不同分为对照组和观察组,各60例。两组患者均予对症治疗,并予依达拉奉右莰醇注射用浓溶液,观察组患者加用丁苯酞氯化钠注射液,均静脉滴注。两组均持续治疗14 d。结果观察组总有效率为90.00%,显著高于对照组的75.00%(P<0.05)。与对照组比较,观察组患者治疗后的美国国立卫生研究院卒中量表评分、改良Rankin量表评分均显著降低,脑源性神经营养因子、胰岛素样生长因子-1、血管内皮生长因子水平均显著升高(P<0.05)。观察组患者缺血性脑卒中发生率为3.33%,显著低于对照组的15.00%(P<0.05)。两组不良反应发生率无显著差异(P>0.05)。结论依达拉奉右莰醇联合丁苯酞治疗TIA,可减轻患者神经损伤,降低其近期缺血性脑卒中发生率。
Objective To investigate the clinical efficacy of edaravone and dexborneol combined with butylphthalide in the treatment of transient ischemic attack(TIA).Methods A total of 120 TIA patients admitted to the hospital from March 2022 to March 2023 were selected and divided into the control group and the observation group based on different treatment regimens,with 60 cases in each group.The patients in the two groups received symptomatic treatment and Edaravone and Dexborneol Concentrated Solution for Injection(intravenous drip),on this basis,the patients in the observation group received Butylphthalide and Sodium Chloride Injection(intravenous drip).Both groups were treated for 14 d.Results The total effective rate in the observation group was 90.00%,which was significantly higher than 75.00%in the control group(P<0.05).Compared with those in the control group,the National Institute of Health Stroke Scale(NIHSS)and modified Rankin Scale(mRS)scores in the observation group significantly decreased after treatment,the brain-derived neurotrophic factor(BDNF),insulin-like growth factor-1(IGF-1)and vascular endothelial growth factor(VEGF)levels significantly increased(P<0.05).The incidence of ischemic stroke in the observation group was 3.33%,which was significantly lower than 15.00%in the control group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Edaravone and dexborneol combined with butylphthalide can alleviate the nerve injury and decrease the incidence of recent ischemic stroke in patients with TIA.
作者
李其敏
王法财
夏一淼
胡悦
LI Qimin;WANG Facai;XIA Yimiao;HU Yue(Lu′an Hospital Affiliated to Anhui Medical University,Lu′an,Anhui,China 237000)
出处
《中国药业》
CAS
2024年第22期119-122,共4页
China Pharmaceuticals
基金
安徽省卫生厅医药科研计划项目[12925KJ2020B44]。
